Madrigal Pharmaceuticals
MDGL
413 hedge funds and large institutions have $12.7B invested in Madrigal Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 79 funds opening new positions, 145 increasing their positions, 130 reducing their positions, and 41 closing their positions.
93% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 41
83% more call options, than puts
Call options by funds: $464M | Put options by funds: $254M
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
12% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 130
9% more funds holding
Funds holding: 380 → 413 (+33)
2% more capital invested
Capital invested by funds: $12.4B → $12.7B (+$217M)
1.33% less ownership
Funds ownership: 103.64% → 102.31% (-1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$145M |
| 2 |
Jane Street
New York
|
+$79.8M |
| 3 |
Holocene Advisors
New York
|
+$78.3M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$68.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$184M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$97M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$79.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$72.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$45.3M |
MDGL Hedge Fund Activity: Q2 2026 in Review
413 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2026, worth a combined $12.7B — up 1.7% from $12.4B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new MDGL positions and 41 closed out — a net gain of 38 holders — while 145 added to existing stakes and 130 trimmed.
The largest buyer was UBS Group, adding an estimated $145M. The largest seller was BlackRock, cutting an estimated $184M.
- 413 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2026, up from 380 in Q1 2026.
- Funds reported $12.7B of Madrigal Pharmaceuticals stock for Q2 2026, up 1.7% quarter-over-quarter.
- 79 funds opened new Madrigal Pharmaceuticals positions in Q2 2026 and 41 closed out, a net change of +38 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2026 was UBS Group, an estimated $145M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2026 was BlackRock, an estimated $184M sold.
Based on aggregated 13F filings for Q2 2026.